Podcasts about cvc capital partners

In this episode John A. Hovanesian, MD, FACS, and Jim Mazzo are live from SightLine at the ASCRS meeting with guests Nicole R. Fram, MD, Kerry D. Solomon, MD, Vance Thompson, MD, and Steve Speares. Welcome to the Eyeluminaries podcast 00:02 Review of episode 32 00:55 Intro of Nicole Fram, MD 01:16 Tell us why the MAHRVELS team is likely to be the leading fundraisers and why you picked your character for the team to portray (The Scarlet Witch)? 02:24 Meeting about complications from cataract surgery, what do you think is the next big phase on how we're going to handle complications with technology? 04:05 Psychology of managing patients/conveying care 05:42 What advice do you give to people who are starting their career? 06:50 Intro of Kerry Solomon, MD 09:30 What do we often get wrong with cataract surgery and what do we often get right? 10:25 How do you stay an entrepreneur and a leading physician? 11:55 What is Operation Sight? How did you create it? 14:19 Where will keratorefractive surgery and lens-based surgery be in 5 or 10 years? 18:30 Intro of Vance Thompson, MD 21:24 What's it like to be ASCRS president? 21:59 What is BRiCS and why is it important? 23:54 You've created a culture; can you talk about that culture you've created at your institute? 29:30 Tell us about your winery! 33:28 Intro of Steve Speares 36:45 ASCRS just wrapped up. Your idea of creating a SightLine with a business approach, what did you do and what was the idea? 38:00 As you look back and you look ahead, what changes do you hope to make? What do you hope your legacy will be at ACSRS? 40:57 Can you expand more on how Washington, DC and Trump administration will impact your society/group? 44:19 Richard Lindstrom in ASCRS hall of fame, tell us your own perspective and a good story 46:29 Preview of episode 34 52:09 Give us your feedback 52:40 Thanks for listening 52:56 Nicole Fram, MD, is an adjunct assistant professor at the John A. Moran Eye Institute at the University of Utah. She is also the secretary for ASCRS, is a member of the Cataract Clinical Committee, and leads the Ophthalmology Quicksand Chronicles podcast with co-host Elizabeth Yeu, MD. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Kerry Solomon, MD, is internationally renowned for LASIK and refractive cataract surgery. He is the co-founder of Operation Sight. He is the former chairman of the ASCRS FDA Committee. Steve Speares, MD, is the executive director at ASCRS. Vance Thompson, MD, is the founder of Vance Thompson Vision and director of refractive surgery in Sioux Falls, SD. He serves as a professor of ophthalmology at the Sanford School of Medicine at the University of South Dakota. Thompson is the immediate past president of ASCRS. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Fram, Speares, Solomon, and Thompson at the time of publication.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news from Washington with guest Mark Leahey. Welcome to the Eyeluminaries podcast :02 Review of episode 31 :40 BVI Medical names a new CCO 2:20 GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions 5:42 Tenpoint submits new drug application for presbyopia combination therapy 7:33 Alcon acquires majority stake in Aurion Biotech 10:29 FDA approves Encelto for macular telangiectasia type 2 14:50 Intro of Mark Leahey 17:28 There is a lot of attention on the HHS restructuring. What are your insights into what has happened to date, and what could happen in the future? 20:10 What do you think about the leadership? 23:44 Let's talk about sustainability. Tell us about the medical device industry's collective interest and challenges in regard to moving toward environmentally sustainable initiatives. 24:59 Let's talk about leadership: Dr. Marty Makary and Dr. Oz. 27:53 Tariffs are an evolving subject. What is the impact on the medical community? What is your impression on how these will affect us in the short term and long term? 33:20 Preview of episode 33 39:27 Give us your feedback 40:23 Team Mah-rvel: the Party for a Purpose 40:41 Thanks 40:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO for the Medical Device Manufacturers Association (MDMA). Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Leahey.

Atenção (disclaimer): Os dados aqui apresentados representam minha opinião pessoal.Não são de forma alguma indicações de compra ou venda de ativos no mercado financeiro.Trump & Tariffs: Last Week Tonight with John Oliver (HBO)https://www.youtube.com/watch?v=5zQ0WewZY50Jon Stewart on Kilmar Abrego Garcia's Deportation and How Trump Fails to Deliver | The Daily Showhttps://www.youtube.com/watch?v=OZbCyBMfy2cPIB da China cresce 5,4% no 1º trimestre em base anual, acima do previstohttps://valor.globo.com/mundo/noticia/2025/04/15/china-registra-crescimento-acima-do-esperado-no-1-trimestre.ghtmlBCE corta juros em mais 25 pontos-base em meio a incertezas sobre tarifas do governo Trumphttps://istoedinheiro.com.br/bce-corta-juros-em-mais-25-pontos-base-em-meio-a-incertezas-sobre-tarifas-do-governo-trump/BTG compra gestora do segmento de wealth management JGP Gestãohttps://www.infomoney.com.br/mercados/btg-compra-gestora-do-segmento-de-wealth-management-jgp-gestao/Méliuz (CASH3) conclui estudo de ampliação da estratégia de tesouraria em Bitcoin e informa os próximos passoshttps://financenews.com.br/2025/04/meliuz-cash3-conclui-estudo-de-ampliacao-da-estrategia-de-tesouraria-em-bitcoin-e-informa-os-proximos-passos/HBSA3 com aumento de capital de R$ 1,17 bihttps://valor.globo.com/empresas/noticia/2025/04/16/hidrovias-do-brasil-levanta-r-117-bi-em-aumento-de-capital.ghtmlRede D'Or vende participação em GSH para fundos da CVC Capital Partners por R$ 1,6 bihttps://exame.com/invest/mercados/rede-dor-vende-participacao-em-gsh-para-fundos-da-cvc-capital-partners-por-r-16-bi/https://valor.globo.com/empresas/noticia/2025/04/17/petrobras-anuncia-reduo-de-338-pontos-percentuais-nos-preos-do-diesel-nas-refinarias-a-partir-desta-sexta.ghtmlhttps://pipelinevalor.globo.com/negocios/noticia/na-azzas-tropa-de-assessores-juridicos-aumenta-em-meio-a-rearranjo-entre-controladores.ghtmlhttps://valor.globo.com/empresas/noticia/2025/04/14/iguatemi-vende-participacoes-no-market-place-e-galleria-shopping-por-r-500-mi.ghtmlhttps://braziljournal.com/azul-lanca-follow-on-que-pode-levantar-ate-r-41-bilhoes/https://www.moneytimes.com.br/mobly-mbly3-recebe-edital-para-opa-de-ate-100-das-acoes-a-r-068-lmrs/https://financenews.com.br/2025/04/mobly-mbly3-vai-cessar-pagamento-de-plano-de-saude-para-ex-conselheiros-e-familiares/https://valor.globo.com/empresas/noticia/2025/04/15/exclusivo-guararapes-dona-da-riachuelo-vai-vender-shopping-midway-mall-dizem-fontes.ghtmlhttps://www.infomoney.com.br/business/mrv-quer-vender-r-14-bilhao-em-terrenos-ate-2029/https://br.investing.com/news/stock-market-news/mrvco-pode-vir-a-se-separar-da-resia-com-entrada-de-investidor-estrategico-1521136https://podcasts.apple.com/br/podcast/her-business-was-thriving-then-came-the-tariffs/id1200361736?i=1000703443731https://podcasts.apple.com/br/podcast/what-an-american-stove-maker-wants-you-to-know-about/id1056200096?i=1000703432201https://podcasts.apple.com/br/podcast/trump-tariffs-hit-mushroom-kingdom/id1302281912?i=1000703124989https://podcasts.apple.com/br/podcast/the-economys-one-guy-problem/id876523888?i=1000703249357https://podcasts.apple.com/br/podcast/the-secrets-of-silk/id1602541473?i=1000701955483https://podcasts.apple.com/br/podcast/a-quick-fix-for-hair-loss-is-making-some-men-sick/id1469394914?i=1000703510789https://podcasts.apple.com/br/podcast/coming-soon-the-future-weapons-of-war/id1169101860?i=1000703552248https://podcasts.apple.com/br/podcast/trapped-abroad-the-man-at-the-center/id1200361736?i=1000703577176https://podcasts.apple.com/br/podcast/trump-trashed-the-iran-nuclear-deal-will-his-be-any-better/id1200361736?i=1000703720781https://podcasts.apple.com/br/podcast/a-rubber-company-supplying-top-tiremakers-faces/id1578096201?i=1000703793911https://podcasts.apple.com/br/podcast/lula-concedeu-impunidade-%C3%A0-ex-primeira-dama-do-peru/id203963267?i=1000703862189

An almost billion-dollar supplement brand portfolio (you've likely never heard of before) just turned CBUM into a corporate sellout. So, let's talk about it! And even if this deal announcement was released publicly on April 1st…I guarantee there's nothing foolish about this M&A activity. But before I give you the legitimate “insider” deep dive insights I can guarantee won't be found anywhere else on the internet…it would be prudent of me to start by covering key press release details from the RAW Nutrition, BUM Energy, and The Quality Group M&A news. And since the bulk of my audience is based within the United States…maybe beginning with the “buy side” would be ideal. The Quality Group was formed in December 2020 with the business combination of the sports nutrition brand ESN and nutritional products brand More Nutrition. ESN was founded in 2004…and is now the sports nutrition categorical leaders within the German market. And then More Nutrition was founded 13 years after ESN but has leveraged a strong social media presence and influencer marketing…landing the nutritional products brand within the top 3 German market categorical leaders. The Quality Group is headquartered north of Hamburg (Germany) and employs more than 1200 people…mostly due to it currently producing more than half its massive product range in house. And while 2024 full-year financial results weren't released yet, The Quality Group reported revenue of around 680 million Euros (or about $750 million dollars) in 2023. Furthermore, the fourth largest global private equity firm, CVC Capital Partners, acquired a majority stake in The Quality Group about three years ago…valuing the business at 800 million Euros (or about $880 million dollars). So, as you can assume from that mid-2022 business valuation to the beforementioned revenue amount reported 18 months later…the two founders staying operationally active, CVC Capital Partners injection of liquidity, and experienced management team CVC brought on have grown the business substantially (and quickly). But maybe it was that last point, surrounding the desire to find a strategic growth partner and them allowing founders to stay operationally active, that ultimately led to this specific M&A transaction. So, effective immediately…RAW Nutrition's Co-Founder and CEO, Domenic Iacovone, and six-time Classic Physique Mr. Olympia Champion and RAW Nutrition co-owner Chris Bumstead will both become co-owners of The Quality Group. Moreover, RAW Nutrition and The Quality Group will remain independent partners as they seek to build long-term value for their consumers. Founded in 2019, Raw Nutrition had moderate success initially but has exploded since Chris Bumstead came onboard as a co-owner in September 2021. Over the last few years, Raw Nutrition has been recognized as the “Brand of the Year” by both GNC and The Vitamin Shoppe. Additionally, RAW Nutrition was recognized in 2024 as not only the fastest-growing sports nutrition brand (but fastest-growing CPG company overall) by Inc. Magazine. And I alluded to this earlier, but BUM Energy, an upstart energy drink brand created by Chris Bumstead in July 2023…was also included within The Quality Group acquisition. And the final portion of my latest principles thinking content will analyze the future outlook and possible implications surrounding the various stakeholders involved...including the RAW Nutrition, BUM Energy, The Quality Group, CVC Capital Partners, and the supplement industry.

De beursweek staat weer voor de deur, en er is genoeg te doen. Bij het bedrijf achter Photoshop moet de topman verantwoording afleggen tegenover de aandeelhouders, vanwege teleurstellende cijfers. Op het Damrak komen er juist nog cijfers naar buiten van CVC Capital Partners. En in Amerika zijn de ogen weer gericht op FED-baas Jerome Powell. Die neemt een nieuwe beslissing over de beleidsrente, maar beleggers willen eigenlijk weten hoe hij naar de rest van dit jaar kijkt. Maar Jean-Paul van Oudheusden van eToro en Markets Are Everywhere let vooral op Nvidia. De topman staat deze week weer op het podium en kan nog wel eens nieuw enthousiasme bij de aandeelhouders uitlokken. In Beurs in Zicht stomen we je klaar voor de beursweek die je tegemoet gaat. Want soms zie je door de beursbomen het beursbos niet meer. Dat is verleden tijd! Iedere week vertelt een vriend van de show waar jouw focus moet liggen.See omnystudio.com/listener for privacy information.

De beursweek staat weer voor de deur, en er is genoeg te doen. Bij het bedrijf achter Photoshop moet de topman verantwoording afleggen tegenover de aandeelhouders, vanwege teleurstellende cijfers. Op het Damrak komen er juist nog cijfers naar buiten van CVC Capital Partners. En in Amerika zijn de ogen weer gericht op FED-baas Jerome Powell. Die neemt een nieuwe beslissing over de beleidsrente, maar beleggers willen eigenlijk weten hoe hij naar de rest van dit jaar kijkt. Maar Jean-Paul van Oudheusden van eToro en Markets Are Everywhere let vooral op Nvidia. De topman staat deze week weer op het podium en kan nog wel eens nieuw enthousiasme bij de aandeelhouders uitlokken. In Beurs in Zicht stomen we je klaar voor de beursweek die je tegemoet gaat. Want soms zie je door de beursbomen het beursbos niet meer. Dat is verleden tijd! Iedere week vertelt een vriend van de show waar jouw focus moet liggen.See omnystudio.com/listener for privacy information.

De beursweek staat weer voor de deur, en er is genoeg te doen. Bij het bedrijf achter Photoshop moet de topman verantwoording afleggen tegenover de aandeelhouders, vanwege teleurstellende cijfers. Op het Damrak komen er juist nog cijfers naar buiten van CVC Capital Partners. En in Amerika zijn de ogen weer gericht op FED-baas Jerome Powell. Die neemt een nieuwe beslissing over de beleidsrente, maar beleggers willen eigenlijk weten hoe hij naar de rest van dit jaar kijkt. Maar Jean-Paul van Oudheusden van eToro en Markets Are Everywhere let vooral op Nvidia. De topman staat deze week weer op het podium en kan nog wel eens nieuw enthousiasme bij de aandeelhouders uitlokken.

Elke week spreken we Frank van den Wall Bake, sportmarketingdeskundige aangesloten bij IVRM Reputatie, over de financiële kant van de sportwereld. Deze week ging het onder meer over de beweging die door Chelsea gestart is om de uitzendrechten terug te stroomlijnen tot één aanbieder, de verkiezingen voor voorzitter van het IOC en over het in het tennis shoppende CVC Capital Partners. Presentatie: Robert Denneman

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Hawaiian Eye meeting with guests Paul Singh, MD, Candy Simerson, Jeffrey Goldberg, MD, PhD, and Roger Goldberg, MD, MBA. Welcome to the Eyeluminaries podcast :02 Review of episode 30 3:23 Intro of Paul Singh, MD 3:40 What are the future trends in glaucoma you're most excited about? 5:10  What challenges do you see in running your practice that didn't exist in your dad's day? 8:36 You've got a great medical office, a very busy consulting and research practice, you play in a band and you have a young family. What advice would you give others in keeping it all in balance? 12:09 Besides your dad and the two of us, who do you look up to in eye care? 14:45 Singh sings a Funkadesi song 18:16 Intro of Candy Simerson 20:36 When you come into a new practice to consult, what are the most common areas you see where improvement can be made? 21:41 What about the finances? What areas in finances do you see where improvement can be made? 24:27 In your many years in ophthalmology, what are the biggest challenges you've experienced? 26:10 What type of practice should consider a sale to private equity? What type of practice should not? 29:34 What advice would you give a company representative who wants to win business from a big ophthalmology practice? 32:29 Intro of the Goldbergs 36:25 Jeff Goldberg, MD, PhD 36:50 Roger Goldberg, MD, MBA 37:21 Jeff, why glaucoma instead of retina? 38:43 Roger, why retina instead of glaucoma? 39:37 Mazzo discusses neuroprotection in retina and glaucoma. 41:14 What is entrepreneurship like today? What's your advice? What is challenging and what is positive? 43:10 Mazzo discusses being realistic about innovations. 48:30 What is private practice like today? 49:31 How do cornea specialists better understand glaucoma specialists? 53:05 How do cornea specialists better understand retina specialists? 54:13 Tell us about emmecell. 55:50 Preview of episode 32 59:19 Give us your feedback 1:00:18 Thanks 1:00:30 Jeffrey Goldberg, MD, PhD, is professor and chair of ophthalmology at the Byers Eye Institute at Stanford University and a member of the National Academy of Medicine. Roger Goldberg, MD, MBA, board certified by the American Board of Ophthalmology and is an active member of the American Society of Retinal Specialists, the Retina Society and the American Academy of Ophthalmology. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Candy Simerson is the senior vice president of practice operations at Vision Integrated Partners. I. Paul Singh, MD, is the president of The Eye Centers of Racine & Kenosha, Ltd., founded in 1981 by his father, Dr. Kanwar A. Singh. He is a founding member of the band, Funkadesi, a mix of Indo-Afro-Caribbean style music. The band tours the world spreading the message “one family, many children.” We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for the Goldbergs, Simerson and Singh at the time of publication.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Steven Dell, MD, about his career and the creation of markets in the field of ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 29 1:28  Bausch + Lomb acquires Elios Vision 2:07  ImprimisRx awarded $34.9 million in trademark infringement suit against OSRX 5:00  Study of atropine-based myopia treatment fails to meet primary efficacy endpoint 7:31  Intro of Steven Dell, MD 11:20 You have created markets with new technologies and companies. Can that continue in today's market? 13:28 Dell discusses presbyopia market development. 14:11 You created a questionnaire that you used in your practice, which has become known as the Dell Questionnaire. What do we need to do better in treating our cataract patients? 16:20 What technologies are going to be the most important in the future? 20:24 What has changed in your office environment, i.e., the role of ODs, admin, staff? 22:00 Dell discusses Lindstrom's Integrated Eye Care Delivery Model. 23:08 What advice would you give a younger Steven Dell? 27:16 Neurotech Pharmaceuticals announced that chief commercial officer Scott Hunter died on Dec. 3. 33:06 Give us your feedback 34:43 Thanks 34:51 Steven J. Dell, MD, is a board-certified ophthalmologist in Austin and the Medical Director of Dell Laser Consultants. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Dell at the time of publication.

In this special crossover episode, Eyeluminaries hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are joined live by Susan MacDonald, MD, and Cathleen McCabe, MD, at Eyecelerator 2024 in Chicago, IL. Intro :07 Welcome to the Eyeluminaries podcast 3:14 In this episode 5:02 Intro of Susan MacDonald, MD, and Cathleen McCabe, MD 5:11 What started you on this journey to do humanitarian work? 5:30 MacDonald discusses the role of parents in defining of happiness. 10:56 Hovanesian discusses the background of his humanitarian work in Armenia. 11:36 What about the funding of these humanitarian projects? 12:50 What are your stories from doing humanitarian work? 14:11 What advice to do you have for physicians who want to get involved in humanitarian work? 18:55 Hovanesian discusses the commonalities in MacDonald and McCabe's humanitarian missions. 22:23 McCabe discusses the commonalities in Hovanesian and MacDonald's humanitarian missions. 22:50 MacDonald discusses how her humanitarian work began. 23:28 Thank you. 27:05 MacDonald talks about the ophthalmic industry and their contribution to humanitarian work. 27:51 McCabe discusses ways physicians can get involved in humanitarian work without having to travel overseas. 28:42 Visit ACE Global, Cybersight or Operation Sight to get involved. 28:54 Mend the Gap podcast 30:49 Preview of episode 30 32:17 Give us your feedback 32:44 Thanks 33:17 Thoughts 33:27 Visit the ASCRS Foundation to get involved in Operation Sight. 34:20 Thank you for listening! 35:17 Don't forget to like and subscribe to Mend the Gap and Eyeluminaries! 35:39 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to podcast@healio.com. Follow us on X (formerly Twitter) @Healio_OSN. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. MacDonald and McCabe report no relevant financial disclosures.

La economía alemana sigue estancada entre la crisis política, la recesión industrial y el descontento ciudadano.. esto se refleja en la confianza empresarial y en el índice Ifo que cae en diciembre de 85,6 a 84,7 cuando los expertos esperaban un 85,5. Más referencias macro de Alemania.. esta vez, el ZEW que sorprendentemente ha dado un salto positivo de 7,4 a 15,7 cuando los expertos esperaban un dato por debajo de 7. El finlandés Olli Rehn señala que la inflación de la eurozona se está estabilizando más claramente en el objetivo del 2% y que esto ayuda a sentar las bases para una mayor reducción de los tipos de interés. La primera ministra italiana Giorgia Meloni avisa de que no apoyarán el acuerdo comercial entre la UE y el Mercosur que se cerró este mes a menos que haya garantías adecuadas para algunos sectores como la agricultura. En clave empresarial, el fondo CVC Capital Partners estudia comprar la participación de Vivendi en Telecom Italia, según citan medios italianos. Entrevistaremos a Andrea Acha Susaeta, experta en comunicación y marca personal para hablar de cómo afecta la marca personal al éxito empresarial. En Expansión y Ciclo, el Banco de España mejora en tres décimas el crecimiento de la economía hasta el 3,1% este año y al 2,5% el que viene. Temas de la actualidad que debatiremos en la Tertulia de Cierre de Mercados con Antonio Alvarez-Ossorio, del despacho de abogados Alvarez-Ossorio Miller, y Juan Pablo Calzada, economista y analista financiero.

Der DAX markierte ein neues Rekordhoch von 20.461 Punkten, ging aber mit einem Minus von 0,2 % bei 20.346 Punkten aus dem Handel. Anleger nutzten die Gewinne bei Rüstungsaktien für Verkäufe: Rheinmetall verlor über 5 %, Hensoldt im MDAX mehr als 6 %. An der Wall Street herrschte nach der Rallye Pause: Dow Jones +0,1 % bei 44.673 Punkten, Nasdaq und S&P 500 jeweils -0,1 %. Die US-Inflationsdaten zur Wochenmitte stehen im Fokus. Firmen im Blick: VW-Warnstreik: Im Stammwerk Wolfsburg ruhte die Produktion 4 Stunden, weitere Standorte betroffen. Hellofresh: -10 % im MDAX nach Kinderarbeitsvorwürfen gegen eine Zeitarbeitsfirma. Zusammenarbeit beendet. CompuGroup: +32,5 % nach Übernahmeangebot von CVC Capital Partners zu 22 Euro je Aktie. Meta/Facebook: Sammelklage wegen Datendiebstahls in Deutschland angekündigt. Warner Bros. Discovery: Einigung mit Comcast über Streamingrechte und höhere Gebühren. Heute im Programm: Assetmanager Matejka über "KI, Marktanteilsveränderungen, Globalopportunismus und die Sprache der Wirtschaft" Boost fürs Depot. Rohstoffe (Öl) nach Assad-Sturz und vor Trump. J. Rädler: "Marktteilnehmer haben wenig Risikoprämie eingepreist" - Kupfer, Gold. Fit4Trading Podcast #62: Aktien, Anleihen, Krypto - was bringt 2025?

In this episode, Jim Mazzo and John A. Hovanesian, MD, FACS, are live from Eyecelerator with Mend the Gap hosts Susan MacDonald, MD, and Cathleen McCabe, MD, discussing their humanitarian work. Welcome to the Eyeluminaries podcast :02 In this episode :31 Intro of Susan MacDonald, MD, and Cathleen McCabe, MD 1:00 What started you on this journey to do humanitarian work? 2:18 MacDonald discusses the role of parents in defining of happiness. 7:47 Hovanesian discusses the background of his humanitarian work in Armenia. 8:24 What about the funding of these humanitarian projects? 9:38 What are your stories from doing humanitarian work? 10:59 What advice to do you have for physicians who want to get involved in humanitarian work? 15:43 Hovanesian discusses the commonalities in MacDonald and McCabe's humanitarian missions. 19:11 McCabe discusses the commonalities in Hovanesian and MacDonald's humanitarian missions. 19:38 MacDonald discusses how her humanitarian work began. 20:16 Thank you. 23:49 MacDonald talks about the ophthalmic industry and their contribution to humanitarian work. 24:39 McCabe discusses ways physicians can get involved in humanitarian work without having to travel overseas. 25:30 Visit ACE Global, Cybersight or Operation Sight to get involved. 25:38 Mend the Gap podcast 27:37 Preview of episode 30 29:05 Give us your feedback 29:25 Thanks 30:05 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Susan MacDonald, MD, is president of Eye Corps and associate clinical professor at Tufts School of Medicine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. MacDonald and McCabe report no relevant financial disclosures.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news and trends and chat with Tom Mitro about his career and impact in ophthalmology. Welcome to the Eyeluminaries podcast :02 Review of episode 26 :58 FDA grants fast track designation to brepocitinib for noninfectious uveitis 1:42  I. Howard Fine, MD, esteemed ophthalmologist, dies 3:54 First subjects dosed in phase 3 trial of phentolamine ophthalmic solution for presbyopia 5:48 LENZ Therapeutics submits NDA for drops to treat presbyopia 7:57 Intro of Tom Mitro 10:40 Tell us about your journey in ophthalmology 12:38 Tell us about the new dry eye drug from Signal 12. 15:53 How much sensation is on the forehead if the drug is well tolerated? 24:13 What are your thoughts on the current ophthalmology market? 26:01 Tell us a funny story about Jim Mazzo and about John Hovanesian. 28:51 Preview of episode 29 33:25 Give us your feedback 34:34 Thanks 34:50 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Tom Mitro is the president and chief operating officer for Aerie Pharmaceuticals. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Mitro at the time of publication.

In this episode, host Sasha Orloff interviews Brad Wiskirchen about his journey with Kount, the AI-driven fraud prevention company he bootstrapped and sold to Equifax for $640 million, while sharing insights from his experience as a founder and now a partner at CVC Capital Partners. For full show notes, visit: https://highlightai.com/share/eec1be56-ae04-4afc-bb24-7ed8523b2176 --

In today's episode, Managing Partner Craig Emanuel sits down with Adrian MacKenzie, Founder and Partner of Five V Capital.Adrian is the founder and a partner of Five V Capital. A highly experienced investor with over 25 years of private equity experience, Adrian has successfully led and managed Five V's investments, including Ascender, Madman Film & Entertainment, Canva, Plenti, Education Perfect, the Probe Group, Zenith Investment Partners, Openway Food Co, Penten and Automic. Before founding Five V Capital, Adrian was a managing partner and board member at leading global private equity firm CVC Capital Partners, where he helped establish the Asia Pacific and Australian offices. Five V have invested across 45 Australian and NZ private businesses, taking an average ownership stake of 30%, and having allocated almost $2B of investor funds on behalf of 400 clients. Since inception, Five V's funds have delivered realised returns of 63% IRR, with an average holding period of 2.9 years per investment.During this podcast, Craig holds in an in-depth discussion with Adrian on the secrets to searching for, selecting and partnering with outstanding Founder-led businesses. Craig and Adrian discuss topics such as an example of a great portfolio company, through to the current PE industry dynamics, through to what shaped Adrian's successful career as a Founder of one of Australia's most prominent PE funds.Disclaimer: The information in this podcast series is for general financial educational purposes only, should not be considered financial advice and is only intended for wholesale clients. That means the information does not consider your objectives, financial situation or needs. You should consider if the information is appropriate for you and your needs. You should always consult your trusted licensed professional adviser before making any investment decision.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Cathleen McCabe, MD, about the ASCRS Foundation and role models in ophthalmology; plus, the latest news in eye care. •    Welcome to the Eyeluminaries podcast :05 •    Review of episode 25 :46 •    Bausch + Lomb acquires Trukera Medical 1:32  •    CMS proposes cutting physician payments for fifth straight year 4:09 •    FDA clears Alcon's Unity cataract system, Unity vitreoretinal cataract system 7:40 •    FDA approves Eylea biosimilar FYB203/Ahzantive 11:07 •    Intro of Cathleen McCabe, MD 13:07 •    American Society of Cataract and Refractive Surgery (ASCRS) has become an important organization to advocate, educate and organize doctors and their practices. As future president of the organization, what vision do you have for the organization? 15:26 •    In reference to your practice, what challenges are you facing and how do you overcome them? 18:59 •    Besides the two of us, who do you admire in ophthalmology? 23:37 •    Tell us about your work, what you do and how you do it. 27:21 •    Preview of episode 27 33:30 •    Thanks 34:58 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Cathleen McCabe, MD, is chief medical officer of Eye Health America and medical director of The Eye Associates in Sarasota, FL. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. McCabe reports no relevant financial disclosures.

Jim Strang is Chair at HgCapital Trust, Adjunct Professor at London Business School, Senior Advisor at Bain & Company, Verdane and CVC Capital Partners, and NED at Pictet Alternative Advisors and BGF Group. Tune in to hear his thoughts on: How does the HgCapital Trust board add value? (2:18) Where do your interests/risk appetites potentially diverge from HgCapital's? (3:35) What are the different products you're considering, and how do you assess their potential value? (4:48) How do you review strategy and performance? (6:20) How do you think about how you will win? (8:30) When would you consider changing your investment manager? (12:27) How do you think about risk? (14:13) In the face of growing geopolitical risk, what options do boards have? (17:58) How can boards react to the risk concentration in cloud computing? (19:15)  Where can investment trust boards add value in terms of accounting policies? (22:15) As a Chair, how concerned are you with valuations of portfolio companies? (24:01) What are the things to look at for, which you've got wrong in the past? (26:55) How do you get comfortable with revenue recognition policies? (28:11) How do you think about board composition and succession planning? (29:42) How are you thinking about discount to NAV? (33:28) ⚡The Lightning Round ⚡(34:55) Show notes and transcript available at https://www.nurole.com/news-and-guides

In this episode of Inside the Rope, David interviews Adrian McKenzie, founder and partner of Five V Capital, an Australian private equity firm focused on the mid-sized market in Australia and New Zealand that boasts a remarkable internal rate of return. David highlights Adrian's notable career, including his tenure at CVC Capital Partners, where he was the youngest ever partner and board member. Adrian shares insights from his vast experience, including both successful investments as well as challenges, such as CVC's investment in Nine Media Group. Adrian discusses his journey from Glasgow to London and New York, detailing his early career in investment banking and his eventual transition to private equity. He reflects on the evolution of the private equity industry and the strategies that have driven success at Five V. Adrian emphasises the importance of aligning with business owners and investing in companies with strong growth potential. The conversation delves into Five V's mid-market focus, targeting companies with earnings between $7-30 million and enterprise values ranging from $50-300 million. Adrian explains the firm's hands-on approach, collaborating closely with management teams to drive value and achieve growth. He also introduces the Horizons product, which offers investors access to mid-market private equity with quarterly liquidity, aiming to provide strong returns with greater flexibility. Adrian shares examples of portfolio companies, such as Sea to Summit and Biopak, and discusses the significant opportunities in the mid-market space driven by intergenerational wealth transfer.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo are live from the Octane OTF with Euan Thomson, PhD, Barry Kuppermann, MD, Jeffry Weinhuff, Ehsan Sadri, MD, FACS, and a special announcement from Rich Small. Welcome to the Eyeluminaries podcast :05 Review of episode 24 1:38 Intro of Euan Thomson, PhD 2:10 What kind of companies did you like working for the most? 3:14 Can you comment on why adoption of digital solutions is slow and what we can do about it? 4:15 Geographically speaking, what is the area that is doing the best to incorporate new practices in medicine? 6:04  Can you talk about any real-world evidence of the value of using digital ophthalmic workflows being realized today? 7:51 Intro of Barry Kuppermann, MD, PhD 13:06 Before his passing, you had several years where you worked with one of the most beloved people in ophthalmology, Roger Steinert. What it was like to work with him? Tell us a fun or inspiring story. 15:51 What are the biggest challenges today in resident/fellow education? What advice would you give graduating residents/fellows? 18:05 GHEI has a strong research program. Does it get tougher each year to fund quality research? 20:01 Where do you want to see GHEI in the long-term? 23:55 Intro of Jeffry Weinhuff 26:02 Tell us about your career before entering eye care investing. What is different about our unique specialty within healthcare? 26:38 Tell us about the Visionary Ventures Fund. Is it looking for new physician investors? 30:24 Announcement from Rich Small 34:12 What does Neurotech do? 36:56 Intro of Ehsan Sadri, MD, FACS, FAAO 38:48 Doctors frequently get asked to make investments in start-up companies. How do you decide if an investment is a good one? 42:13 What do you think have been the most innovative companies in eye care during your career? 45:09 Preview of episode 26 49:33 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Barry Kuppermann, MD, PhD, is the Roger F. Steinert professor, chair of the department of ophthalmology and director of the Gavin Herbert Eye Institute at the University of California, Irvine. He also holds a joint appointment with the department of biomedical engineering at UC Irvine. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Ehsan Sadri, MD, FACS, FAAO, is board-certified, fellowship-trained in treating LASIK, cataract and glaucoma surgeries with locations to serve patients in Newport Beach, Santa Ana and Orange. He is also CEO and founder of Visionary Eye Institute and general partner and co-founder of Visionary Ventures Fund (Visionaryvc.com). Rich Small is CEO and member of the board of directors for Neurotech. Euan Thomson, PhD, is the president of ophthalmic devices and head of digital business unit at Carl Zeiss Meditec Inc. Jeffry Weinhuff is the chief investment officer and managing partner of Visionary Ventures Fund, a later-stage venture fund focused on investing in drugs and devices for the eye. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an advisor for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus. Sadri is the CEO and founder of Visionary Eye Institute and general partner and co-founder of Visionary Ventures Fund. Weinhff is the managing partner of Visionary Ventures Fund. Small is chief executive officer and member of the board of directors for Neurotech. Thomson is the president of ophthalmic devices and head of digital business unit at Carl Zeiss Meditec Inc. Weinhuff is the managing partner of Visionary Ventures Fund.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss leadership in eye care with guest Jack T. Holladay, MD, MSEE, FACS. Brought to you by Johns Hopkins University. •  Welcome to the Eyeluminaries podcast :21 •  Review of episode 23 1:19 •  Blog by John A. Hovanesian, MD, FACS 3:10 •  Merck to acquire EyeBio 4:14 •  FDA approves aflibercept biosimilars Yesafili, Opuviz 6:26 •  Aurion Biotech completes enrollment in phase 1/2 corneal edema cell therapy trial 8:43 •  Intro of Jack Holladay, MD, MSEE 11:10 •  How did you develop a passion for optics? Did you know it was going to be your future? 13:50 •  Holladay's life-threatening situation 16:21 •  Holladay's experience teaching residents 23:50 •  Holladay's optics strategy for improving his golf game 28:33 •  Preview of episode 25 32:25 •  Feedback, questions and guest suggestions at eyeluminaries@healio.com 32:45 Jack T. Holladay, MD, MSEE, FACS, is a clinical professor of ophthalmology at Baylor College of Medicine and retired from clinical ophthalmic practice. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Centricity Vision, IanTech, Lensgen and Visus.

Welcome to the Thursday edition of Winning Cures Everything! On today's show we're discussing:Big 12 Naming Rights and Private Equity: Explore the potential rebranding of the Big 12 with Allstate and the possibility of partnering with CVC Capital Partners for a significant cash infusion.Conference USA Naming Rights: Discover Conference USA's rebranding efforts and their potential partnership with Globe Life.SEC TV Schedule Announcement: Get the full breakdown of the SEC's TV schedule, including marquee games set for noon EST.Brent Key's Georgia Dislike: Hear Brent Key's strong words about Georgia and the importance of rivalry intensity in college football.Additional Updates:Texas is hosting an SEC welcome party with Pitbull.Oklahoma WR Deion Burks arrested for DUI and speeding.Northwestern AD Derek Gragg transitioning to VP of Athletic Strategy.Southern Miss DB MJ Daniels tragically passed away due to a shooting.News of the Weird:23 sets of twins graduating from Pollard Middle School in Needham, MA.Want to become a YouTube member? Click here: https://www.youtube.com/channel/UC4ckuVJmQrZp4cotMWOg6eg/join

Welcome back to the Alt Goes Mainstream podcast.Today's episode features a masterclass in private markets from a guest who has seen it all.Jim Strang is a deeply experienced private equity professional who has been part of the industry as a GP, LP, investor, consultant, and now a teacher, board member, and advisor to a number of firms.I'd probably have to spend a good few pages going through everything that Jim has done and is currently doing in private markets. He's a practitioner and a teacher, an expert and an operator. After an illustrious career that was punctuated as Chairman EMEA of Hamilton Lane, one of the largest LPs in private markets globally, he now serves in a number of board and advisor roles, which include Chairman of the Board at HgCapital Trust plc, Senior Advisor to CVC Capital Partners, Advisor at Bain & Company, and Director at Pictet Alternative Advisors.Jim and I had a fascinating conversation about the evolution of private markets and what the future holds for large and small funds alike, as well as LPs. We discussed:The step function changes that take private markets from $15T to $30T of AUM.Why traditional asset managers may struggle to replicate the capabilities of alternative asset managers in private markets.The importance of partnerships having a clear ambition and alignment if they want to build a scaled platform.The challenges that managers in the middle face as large platforms and specialist managers are the differentiated firms in the eyes of LPs.Why GPs need to find innovative solutions to address the needs of different types of investors.Why building a strong brand is crucial to success in the wealth channel.Thanks Jim for coming on the show to share your wisdom and experience on private markets.This episode of Alt Goes Mainstream is brought to you by Ultimus Fund Solutions, a leading full-service fund administrator for asset managers in private and public markets. As private markets continue to move into the mainstream, the industry requires infrastructure solutions that help funds and investors keep pace. In an increasingly sophisticated financial marketplace, investment managers must navigate a growing array of challenges: elaborate fund structures, specialized strategies, evolving compliance requirements, a growing need for sophisticated reporting, and intensifying demands for transparency. To assist with these challenging opportunities, more and more fund sponsors and asset managers are turning to Ultimus, a leading service provider that blends high tech and high touch in unique and customized fund administration and middle office solutions for a diverse and growing universe of over 450 clients and 1,800 funds, representing $500 billion assets under administration, all handled by a team of over 1,000 professionals. Ultimus offers a wide range of capabilities across registered funds, private funds and public plans, as well as outsourced middle office services. Delivering operational excellence, Ultimus helps firms manage the ever-changing regulatory environment while meeting the needs of their institutional and retail investors. Ultimus provides comprehensive operational support and fund governance services to help managers successfully launch retail alternative products. Visit www.ultimusfundsolutions.com to learn more about Ultimus' technology enhanced services and solutions or contact Ultimus Executive Vice President of Business Development Gary Harris on email at gharris@ultimusfundsolutions.com.We thank Ultimus for their support of alts going mainstream.Show Notes00:00 Introduction and Sponsor Message02:06 Podcast Theme Song02:44 Guest Introduction: Jim Strang02:52 Jim Strang's Career Overview05:35 State of Private Markets: Challenges and Opportunities08:04 Fundraising Dynamics in Private Equity11:25 European Private Equity: Evolution and Insights15:01 Scaling Challenges and Ambitions in Private Equity25:41 Technology and Innovation in Private Equity32:47 Challenges in Organizational Analysis33:56 Psychological Assessments in Investment Decisions35:48 Effective Questioning Techniques for LPs36:29 Transparency and Culture in Investment Firms37:34 Evolution of Asset Management38:41 Public vs. Private Asset Managers40:27 Generational Shifts in Private Equity Firms44:12 Growth and Democratization of Private Markets48:40 Liquidity Challenges in Private Markets54:45 Quick Fire Round: Insights on Private Markets01:00:10 Entertainment Investments: Music Royalties and Sports01:04:02 Conclusion and Final Thoughts

Dat zegt Nico Inberg over de koersreactie op de kwartaalcijfers van ABN Amro. De bank doet volgens hem bijna alles goed, maar ging onderuit op de beurs. De winst viel flink hoger uit dan verwacht. Alleen de bank heeft minder vet op de botten dan waar beleggers op hoopten. Daardoor is er minder ruimte voor cadeautjes, zoals dividend en eigen aandeleninkoop. Bij Google gaat de zoekmachine op de schop. Die wordt volgepropt met AI. Leuk voor de gebruiker, maar in deze aflevering bespreken we hoe moederbedrijf Alphabet daar geld uit denkt te persen. Iedereen keek verder vol spanning naar het Amerikaanse inflatiecijfer. Dat zakte vorige maand naar 3,4 procent, geheel in lijn met de verwachting. Beleggers wereldwijd hopen dat een afgekoelde economie betekent dat Powell sneller dan gedacht de rente verlaagt. Laat Nico nou net een kort lijntje hebben met de Fed-baas... Tot slot bespreken we een strafrechtelijk onderzoek naar Boeing, de Londense beursgang van computermaker Raspberry Pi en het aandeel GameStop dat weer met beide benen op de grond staat.  See omnystudio.com/listener for privacy information.

Distribution grids are facing new challenges. On the one hand, they experience a growth of local demand, with EV charging, heat pumps and datacenters. On the other, they must accommodate with the fast deployment of decentralised energy such as rooftop solar and batteries. How to reconcile those challenges while maintaining grid stability? And how can Utilities, hooked up on rates and CAPEX start thinking differently and adopt new technologies? Beyond the regulatory changes and technical investments, some cultural shifts need to be implemented. And a lot of solutions are digital.That's the job of our guest, Robert Denda. Robert is CEO of Gridspertise, a new company carved out two years ago out of ENEL. Previously, he was Head of Innovation & Industrialization (since June 2021) at the Enel Global Infrastructure and Networks and Head of Network Technology and Innovation (since June 2015) at the same business line of the Enel Group, leading the development of and application of digital grid technologies at the largest privately-owned international operator of power distribution grids, serving 74 million customers.  Gridspertise today is an independent company jointly controlled by is a 50/50 JV between Enel and investment fund CVC Capital Partners, valued almost 1bnEUR, headquartered in Italy but also present in Spain, Brazil, USA, Germany and Scandinavia the Nordics. Its Enterprise Value was valued 625M EUR at the time of the transaction, with potential deferred payments that could bring the enterprise value up to 1bn EUR.Our conversation encompasses several themes, from smart meters to sensors, from cyber security to AI, from performance to business trends. Solutions are being implemented daily to speed up the Energy Transition.   We thank Amundi, EU largest Asset Manager, for supporting the show

In this week's episode of The Deal Room, we dive into three major headlines shaking up the world of corporate finance.Explore BHP's ambitious £31bn bid for Anglo American, recently rejected but potentially set for a comeback. Discover the strategic insights driving this high-stakes deal and the hurdles it faces.Get the inside scoop on Goldman Sachs' bold move, relocating top talent from London to Paris amidst Brexit uncertainties. Could Paris be the next hotspot for finance graduates?Plus, unravel the story behind CVC Capital Partners' successful IPO, as the firm and its investors raise €2bn, marking a significant milestone in Europe's private equity landscape.Tune in and learn about finance with real news events happening today!*****Take our free M&A Finance Accelerator simulation in partnership with UBS www.amplifyme.com/mafa Hosted on Acast. See acast.com/privacy for more information.

De belangrijkste dag van de beursweek is nu, deze vrijdag. CVC Capital ging succesvol naar Beursplein 5. De grootste beursgang in jaren. En liefhebbers van tech konden reageren op de kwartaalcijfers van Snap, Microsoft en Alphabet. Alle drie deden ze het beter dan verwacht. Alphabet, eigenaar van Google, kwam zelfs met cadeautjes. Het gaat voor tientallen miljarden aan eigen aandelen inkopen én er wordt dividend uitgekeerd! En dat dividend, dat is bijzonder. Dat doet het bedrijf nu pas voor het eerst. Beleggers moesten even geduld hebben, want het bedrijf werd in 1998 opgericht. Deze aflevering kijken we of Alphabet door uit te delen, meer waard wordt. En bekijken we welk bedrijf zich nu mag kronen tot AI-koning. Zowel Microsoft als Alphabet claimen de troon en zeggen dat ZIJ er het beste voorstaan. Snap was vaak de kneus van de techbedrijven. Kwartaal op kwartaal kwam het met onvoldoendes, maar nu doet het slechtste jongetje van de klas het ineens goed! De onderneming achter Snapchat overtreft de verwachting van analisten. Verder praten we je bij over BasicFit. Geen tech, wel een krachtpaster die verder wil groeien. Je hoort meer over Philips en de slaapapneu-affaire en natuurlijk die beursgang van CVC Capital. Dat was dus een succes, maar is dat ook een succesverhaal op de lange termijn?  Tot slot hoor je welke bedrijven er volgende week met cijfers komen en waar je op moet letten. Spoiler: Apple.See omnystudio.com/listener for privacy information.

Het hing al tijden in de lucht, maar vanochtend was het dan zover: CVC Capital Partners ging officieel de beurs op in Amsterdam. Hoe verliep deze beursintroductie? Beursnerd en Beursnerd XL Iedere werkdag iets na elf uur werpt de Beursnerd in gesprek met presentator Thomas van Zijl een blik op de AEX, waarbij hij of zij de diepgang niet schuwt. Daarnaast is er donderdag om tien voor twaalf een langere beursanalyse. Die neemt Beursnerd XL Jochem Visser voor zijn rekening.See omnystudio.com/listener for privacy information.

De directie van Adyen trok de afgelopen maanden alles uit de kast om de zorgen bij aandeelhouders weg te nemen. Om het aandeel op te poetsen. Maar na vandaag lijkt Adyen terug bij af. Een mokerslag voor de beurskoers. Ook het aandeel Meta werd gedumpt. Daar schrikken beleggers van het gat in de hand van de ceo. Deze aflevering bespreken we de zorgen van aandeelhouders. Twee totaal verschillende bedrijven, maar bij beide zijn er zorgen over de toekomst. Zijn die tijden van extreme marges iets van het verleden, of kunnen ze dat ook de komende jaren herhalen?  Ook hoor je meer over Unilever. Dat doet het weer goed, behalve in Europa. Daar kan het alleen maar groeien door de prijzen te verhogen. Al lijkt er goed nieuws, en dat heeft te maken met duurzaamheid. Of in dit geval: het beetje bij beetje laten vallen van de duurzaamheidsdoelen. De kwartaalcijfers van Besi, daar staan we ook bij stil. Beleggers wisten niet helemaal of het bedrijf nu met goed of slecht nieuws kwam.  Tot slot nog een Amerikaanse beursgang Rubrik (een waar Microsoft geld in stopt), over de goede verkopen van Hermes én over Peter Wennink. Sinds vandaag geen ceo van ASML meer, maar nog even en we vinden hem terug in de Quote 500!See omnystudio.com/listener for privacy information.

ASML heeft boos met de vuist op tafel geslagen, en krijgt er allerlei toezeggingen voor terug. Het kabinet trekt miljarden uit om de chipmachinemaker binnen de landsgrenzen te houden. Nu ligt er ook een intentieverklaring van ASML en de regio Eindhoven. ASML mag flink uitbreiden: 143 voetbalvelden aan extra fabriek en 20.000 nieuwe medewerkers. Krijgt het aandeel ook ruimte om te groeien?  Op de elektrische automarkt is de prijzenoorlog volledig aan het escaleren. Tesla haalt op zo ongeveer alle continenten duizenden euro's van de prijs af. Dat moet de verkoopcijfers aanjagen, want die zijn slecht. Maar het jaagt beleggers ook op de kast.  En bij CVC Capital Partners heerst een 'grote stappen snel thuis'-mentaliteit. De investeerder kondigde vorige week nog aan naar de Amsterdamse beurs te willen, en laat nu weten dat aanstaande vrijdag het al zo ver is. De beursgang moet minstens 1,6 miljard euro gaan opleveren. En daarmee wordt het waarschijnlijk de grootste beursgang in Amsterdam in jaren.  See omnystudio.com/listener for privacy information.

Meer omzet, meer winst, maar vooral: méér abonnees. Het aantal abonnementen op Netflix steeg met negen miljoen in het vorige kwartaal. Toch reageerden beleggers furieus. En dat heeft alles te maken met de beslissing om te stoppen met het delen van het aantal abonnees. Jarenlang kon Wall Street varen op die belangrijke graadmeter, maar nu wordt 'ie bij het grofvuil gezet. En daar is niemand blij mee (behalve Netflix). Elon Musk heeft het zwaar. Analisten zijn het met hem eens, want hun verwachtingen voor Tesla kelderen. Helemaal nu het bedrijf ook nog eens 4000 cybertrucks terug moet roepen. Probleempje met het gaspedaal. Dat kan vast komen te zitten. In aanloop naar Unilever volgende week bekijken we de cijfers van Procter & Gamble. Na Danone zegt ook dat bedrijf dat het tijdperk van prijsverhogingen binnenkort over is.  Verder bespreken we het belangrijkste chipnieuws met de kennis van nu: wat zeggen de cijfers van ASML en TSMC over die van BESI en ASMI volgende week? Tot slot blikken we terug op een week bomvol bijzonder nieuws.  See omnystudio.com/listener for privacy information.

Je zal de mail maar krijgen: 'Sorry, tien procent van de mensen gaat eruit en jij bent één van de gelukkigen.' Dat is zo ongeveer wat Elon Musk schrijft aan medewerkers van Tesla. De automaker begon de prijzenslag in China om marktaandeel te veroveren, maar dat was niet genoeg. De Chinese export steeg vorig jaar met bijna zestig procent, Duitse automakers verkopen inmiddels ook elektrische auto's en Musk vecht om de marges intact te houden. Verder hebben we het over olie en het Midden-Oosten. Beleggers lijken hun schouders op te halen bij de grootschalige raketaanval van Iran op Israël. Voor degenen zonder scrupules zijn er nog defensiebedrijven, maar die zijn inmiddels ook flink prijzig op de beurs. Apple blijft even duur als altijd, maar wordt misschien wat goedkoper. De verkoop van iPhones in het eerste kwartaal viel tegen. De kwartaalcijfers laten nog even op zich wachten, maar een internationaal onderzoeksbureau zag dat de verkoop van het vlaggenschip van Apple met bijna 10% is gedaald. Het is weer tijd voor een grote beursgang in Amsterdam. Na Douglas wil ook de eigenaar naar de beurs. CVC Capital Partners, waar ook Lipton en de Formule 1 onder vallen, wordt maar liefst 15 miljard euro waard op de beurs. Wel is het nog even de vraag wie er meer verdient aan private equity: de belegger in het bedrijf, de belegger in de fondsen, of toch gewoon de baas. Goldman Sachs, toevallig één van de begeleiders van de beursgang van CVC, is weer helemaal terug. De zakenbankiers in de torens in New York zien het aantal deals weer stijgen en ook de handelsinkomsten droegen bij aan het beste kwartaal sinds 2021.  See omnystudio.com/listener for privacy information.

Investeringsmaatschappij CVC (straks CVC Capital Partners) maakte maandagochtend bekend dat het, na meerdere keren uitstel, een beursnotering wil krijgen in Amsterdam. Waarom wil de eigenaar van onder meer Douglas zo graag een notering op het Damrak? Beursnerd en Beursnerd XL Iedere werkdag iets na elf uur werpt de Beursnerd in gesprek met presentator Thomas van Zijl een blik op de AEX, waarbij hij of zij de diepgang niet schuwt. Daarnaast is er donderdag om tien voor twaalf een langere beursanalyse. Die neemt Beursnerd XL Jochem Visser voor zijn rekening.See omnystudio.com/listener for privacy information.

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo chat with Terry Kim, MD, and Stephen Lane about their careers and transitions at Alcon. Brought to you by Johns Hopkins University. Welcome to the Eyeluminaries podcast :21 Review of episode 22 1:27 Intro of Stephen Lane 2:41 Intro of Terry Kim, MD 6:02 Lane: Why retire? What's next? 7:54 Kim: Why the move to the industry? 10:35 Lane: What does a chief medical officer do? What did you learn from the time you went from practice to CMO, and what were some of the surprises? 13:14 Kim: What do you see as some of the challenges you will be facing? 18:19 Lane: What will you miss the most about being a CMO? 21:03 In your experience, how do you navigate transitions in a company and lead without losing focus? 24:22 Preview of episode 24 30:45 Feedback, questions and guest suggestions at eyeluminaries@healio.com 31:34 Thanks for listening 32:08   John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Terry Kim, MD, is a professor of ophthalmology at Duke University Eye Center. Stephen Lane is a founding partner of Associated Eye Care. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

US equity futures are indicating a broadly unchanged open as of 04:45 ET. This follows mixed markets in Asia, while European equity markets are mostly higher. The market is in waiting mode for several potential catalysts, particularly the March CPI due later today. We also have the ECB decision on Thursday and the start of bank earnings season on Friday. In overseas developments, Reserve Bank of New Zealand left its official cash rate unchanged as expected and reiterated rates need to remain restrictive for a sustained period. Companies mentioned: CVC Capital Partners, Tesco, Taiwan Semiconductor

In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news in eye care and chat with Wiley A. Chambers, MD, about his career in the FDA and his plans for retirement. Brought to you by Johns Hopkins University Welcome to the Eyeluminaries podcast :21 Review of episode 21 :50 Clobetasol propionate ophthalmic suspension 0.05% approved for postop inflammation, pain 2:49 PulseSight Therapeutics launches with focus on non-viral gene therapies 5:31 FDA clears first investigational new drug application for neuropathic corneal pain 7:59 APX3330 ‘promising' oral treatment option for slowing progression of diabetic retinopathy 10:20 H. Dunbar Hoskins Jr., decorated glaucoma specialist, dies 11:55 Intro of Wiley A. Chambers, MD 13:36 What are you most proud of accomplishing in your 36 years at the FDA? 15:54 What about oral therapies for the eye? 17:30 What do you wish you could change? 18:46 What advice would you give an innovator with a new drug idea? 21:31 What's next for Wiley Chambers? Ocular Advisors, LLC 23:17 What has changed since you left the FDA? 25:11 Second annual drug name awards: The Year of Vs and Ys 27:04 “Needs to buy a vowel” award 28:49 “i before e” award 30:23 “Most likely to be misspelled” award 31:44 “Is there a way to pay for it?” award 33:17 The cutesy award 34:29 “Need an award” award 36:10 Preview of episode 23 38:17 Feedback, questions and guest suggestions at eyeluminaries@healio.com 39:59 Thanks for listening 39:36 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Wiley A. Chambers, MD, is a clinical professor of ophthalmology and adjunct assistant professor of computer medicine at The George Washington University and owner of Ocular Advisors, LLC. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian. Disclosures: Chambers is the owner of Ocular Advisors, LLC. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.

Apple zou serieuze gesprekken voeren om de AI-technologie van Google op zijn iPhones te krijgen. Een flater voor Apple, want het moet bij de concurrent aankloppen omdat het niet gelooft in zijn eigen kunstmatige intelligentie. En voor Google is het een aantrekkelijke deal. Het kan een flinke zak geld opleveren, maar ook gebruikers wegsnoepen bij concurrerende AI-modellen. Nog meer AI in deze aflevering. Het gaat ook over Nvidia. De chipmaker staat aan het begin van vier dolle dagen. Het trapt misschien wel het belangrijkste evenement ooit af. De verwachting is dat Nvidia met een nieuwe chip komt om AI mee te trainen. En het bedrijf laat ook weten waar het de komende jaren op wil focussen. De Amsterdamse beurs ziet dat het animo voor een beursgang bij bedrijven toeneemt. Maar het zijn niet onze eigen Nederlandse bedrijven die een plekje in de AEX, Midkap of SmallCap willen, maar juist internationale spelers. Zo heeft CVC Capital Partners, de eigenaar van Douglas, de plannen voor een IPO weer afgestoft. Maar ook de afgelopen jaren waren het vooral buitenlandse bedrijven die de beurs betraden. En we hebben besloten om het de hele week te hebben over de beste besluiten van onze gasten. We beginnen bij het begin, namelijk: starten met beleggen.  See omnystudio.com/listener for privacy information.

Quick episode summary John A. Hovanesian, MD, FACS, and Jim Mazzo sit down with guests Eric D. Donnenfeld, MD, Calvin C. Roberts, MD, Mark L. Baum and Jeannette Bankes to discuss private equity, industry breakthroughs and more. Welcome to the Eyeluminaries podcast :00 Review of episode 20 1:16 Intro of Eric D. Donnenfeld, MD 2:06 Understanding the role of private equity: where does it stand and where is it going? 4:22 Do you see a relief in interest rates and the pace picking up for private equity in the years ahead? 7:19 What are the technologies that you are most excited about? 8:17 What are the things to watch out for? 11:08 Do you have an interesting James Worthy story? 13:34 Intro of Calvin C. Roberts, MD 15:21 Transplanting eyes and Advanced Research Project Agency for Health (ARPA-H) 15:48 How does a chief medical officer work within a company? 18:56 How is what ARPA-H doing different than simply transplanting an eye? 20:42 Intro of Mark L. Baum 26:06 What does the rebranding of the company mean? 27:00 Pharmaceutical names: VEVYE 28:22 How will you market VEVYE in the US? 29:48 Fortisite 31:59 What is the future of the company? 32:47 What do you think of Dr. Wiley Chambers' retirement? 34:09 Intro of Jeannette Bankes 36:51 Describe your last five years in the ophthalmic space: the good, the bad, the ugly 39:16 ·       If you could change anything in the ophthalmic industry, what would it be? 42:53 ·       How excited are you about robotics? 44:06 ·       Tell us about your promotion 44:52 ·       How can we develop a more diverse leadership in ophthalmology? 45:31 Preview of episode 22 48:01 Feedback, questions and guest suggestions at eyeluminaries@healio.com 48:18   Jeannette Bankes is the president and general manager of global surgical franchises for Alcon. Mark L. Baum is the founder, chairman of the board and chief executive officer of Harrow. Eric D. Donnenfeld, MD, is a cornea, laser cataract and refractive surgeon for OCLI Vision. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Calvin C. Roberts, MD, is a program manager for health science futures at ARPA-H. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Bankes is the president and general manager of global surgical franchises for Alcon. Baum is the founder, chairman of the board and chief executive officer of Harrow. Donnenfeld reports consulting widely across the ophthalmic industry with relevant disclosures in this episode as a consultant with Alcon, Bausch + Lomb, LensGen, Ocular Therapeutix and Omeros. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision. Roberts is program manager for health science futures at ARPA-H.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Vance Thompson, MD, Adrienne Graves, PhD, Sean Ianchulev, MD, and Kristen Harmon Igenito, live from AAO Eyecelerator. Welcome to the Eyeluminaries podcast :01 Review of episode 19 1:31 Intro of Vance Thompson, MD 2:13 What is the secret to your success? 3:54 How many fellows have you trained? 5:20 How has having a fellowship training program at Vance Thompson Vision impacted your practice? 6:23 What are the two recently approved products that you are amazed by? 10:02 What is your favorite wine? 12:55 What is your favorite dad joke? 15:25 Intro of Adrienne Graves, PhD 16:59 How does your background help you serve in the companies and non-profits you work with? 19:43 What do strategics do for companies? 24:13 Prescription drug names 25:53 Intro of Sean Ianchulev, MD, MPH 29:45 How do your ideas evolve? 31:53 ·       Who or what inspires you? 45:58 Intro of Kristen Harmon Ingenito 49:39 How is the software different? 51:45 How is market research changing? 55:19 What are you most optimistic about in terms of trends? The most challenging? 57:18 At what point in your life did you decide to work in market research? 59:05 Preview of episode 21 1:02:32 Feedback, questions and guest suggestions at eyeluminaries@healio.com 1:02:40   Adrienne Graves, PhD, serves as an independent director on the boards of Iveric Bio, Nicox S.A., Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix and serves as director on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Sean Ianchulev, MD, MPH, is a Harvard-trained physician-scientist, a professor of ophthalmology and the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. Kristen Harmon Ingenito has more than a decade of experience in the ophthalmic industry, with nine of those years analyzing data and reporting for Market Scope. Kristen's industry experience began in 2005 at Market Scope, where she served in many roles, including editing, analysis, sales, and marketing. She then joined an ophthalmic patient education software company, where she worked closely with physicians to help drive value in all aspects of their practices, while also training incoming executives on the business of eye care. She returned to Market Scope with added experience to help expand the company's portfolio of products and services. Source: Market Scope Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Vance Thompson, MD, is a board-certified ophthalmologist who specializes in refractive surgery including laser vision correction, implant vision correction and advanced cataract surgery and is the director of refractive surgery at Vance Thompson Vision. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Graves serves as an independent director on the boards of Iveric Bio, Nicox S.A., Greenbrook TMS NeuroHealth, Surface Ophthalmics, Qlaris Bio, and TherOptix and serves as director on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, and the Foundation Fighting Blindness Retinal Degeneration Fund. Hovanesian consults widely in the ophthalmic field. Ianchulev is the head of innovation and technology at New York Eye and Ear Infirmary founder and chairman of Iantrek Inc and Eyenovia and serves as a board member for the American Society of Cataract and Refractive Surgery Foundation and AEYE Health. Ingenito develops products and provides services to Market Scope. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision.

Israeli troops have entered Gaza City, European private equity group CVC Capital Partners has postponed plans to float until next year, and central banks are hitting pause on interest rate rises while inflation stays strong.Mentioned in this podcast:Israeli army attempts to ‘encircle' Gaza City as Joe Biden calls for pause in fightingCVC Capital Partners postpones plans for Amsterdam listingCentral banks hold interest rates at a scary timeBoE expected to leave rates unchanged as inflation remains strongAI companies agree to government tests on their technology to assess national security risksSam Bankman-Fried convicted of fraud over FTX's collapseThe FT News Briefing is produced by Fiona Symon, Sonja Hutson, Kasia Broussalian and Marc Filippino. Our engineer is Monica Lopez. Additional help by Sam Giovinco, Peter Barber, Michael Lello, David da Silva and Gavin Kallmann. Topher Forhecz is the FT's executive producer. The FT's global head of audio is Cheryl Brumley. The show's theme song is by Metaphor Music.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Peter Slack, Greg Kunst, Rich Small and Uday Devgan, MD, FACS, FRCS, live from OSN New York. Welcome to the Eyeluminaries podcast :01 Review of episode 18 :18 Intro of Peter Slack 1:47 How did OSN start? 2:35 When did you get into meetings and where do you see meetings going? 5:40 Where do you see media going? 7:46 How did you end up running the Hawaiian Eye Meeting? 10:53 Intro of Greg Kunst 13:59s What will be the biggest challenges introducing a new paradigm for a traditionally surgical disease? 14:52 What can you tell us about Aurion's plans for cell therapy in other front and back of the eye disease, in addition to endothelial cell disease? 17:04 What should I be telling my patients who have future need for endothelial keratoplasty? 19:17 What is the status of Aurion in Japan? Is the competition on the horizon? 22:13 Intro of Rich Small 25:53 Why are you excited about the Encapsulated Cell Therapy Platform? 27:12 Why MacTel? 31:52 What is the status of the Neurotech BLA? 32:26 ·       Give us a good Jim Mazzo story 34:38 Intro of Uday Devgan, MD, FACS, FRCS(Glasg) 37:05 Tell us about how you got started producing one video per day 38:10 Tell us a story about a doctor from far away who is influenced by your teaching 40:38 If you could change one thing in residency training today, what would it be? 41:59 Preview of episode 20 43:51 Feedback, questions and guest suggestions at eyeluminaries@healio.com 44:04   Uday Devgan, MD, FACS, FRCS(Glasg), is Healio|OSN section editor for Ocular Surgery News. He is in private practice, specializing in cataract and refractive surgery, at Devgan Eye Surgery in Los Angeles and a full partner at Specialty Surgical Center in Beverly Hills, California. He has previously served as full clinical Professor of Ophthalmology at the Jules Stein Eye Institute at the UCLA School of Medicine as well as Chief of Ophthalmology at Olive View-UCLA Medical Center and has been actively involved in resident surgical teaching for over two decades. He owns and operates CataractCoach.com. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Greg Kunst is president, chief executive officer and board member at Aurion Biotech. He is focused in areas such as R&D, clinical development, corporate development, strategy, marketing, commercial, business development, market access and medical affairs with extensive knowledge of global health care markets (North America, Latin America, Europe, Asia), global commercialization and market development, upstream and downstream marketing, market access, and medical affairs for medical device, drug delivery systems, diagnostic systems, biotechnology, cell therapies, gene therapies, biologics, and pharmaceutical products. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Peter N. Slack is president and chief executive officer of The Wyanoke Group. Peter is past-Chairman and a current member of the Board of Trustees for the Center for Family Services, a nonprofit human services agency. Other professional titles and memberships have included Board of Directors of the International Association of Association Management Companies and Board of Directors of the American Medical Publishers Association. In addition, Peter is President of the Broadway Theatre of Pitman in Pitman, NJ.  Disclosure: The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast. Rich Small is chief executive officer and member of the board of directors for Neurotech. He originally joined Neurotech in July 2007 as the company's chief financial officer. He has in excess of 30 years of both private and public life sciences experience and more than 40 years of overall financial and operational management. Previously Rich served as Senior Vice President and Chief Financial Officer of Point Therapeutics, a publicly traded biotechnology company focused in developing treatments for various cancers. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Devgan owns and operates CataractCoach.com. Hovanesian consults widely in the ophthalmic field. Kunst is president, chief executive officer and board member at Aurion Biotech. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Slack is president and chief executive officer of The Wyanoke Group. Small is chief executive officer and member of the board of directors for Neurotech. The Wyanoke Group is the holding company for Healio, the producer of the Eyeluminaries podcast.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Julia Haller, MD, about the latest developments in retina, residency training and more. Welcome to the Eyeluminaries podcast :01 Review of episode 17, live from Octane OTF :41 Bausch + Lomb makes a number of big moves under the new Brent Saunders regime 1:40 Mark Baum and Harrow Health have also been making a number of acquisitions 3:59 FDA approves Xdemvy for Demodex blepharitis treatment 5:45 Former CEO of Johnson & Johnson Alex Gorsky elected lead director of Neurotech's board 7:47 John begins new clinical committee for ASCRS, digital 9:32 Julia Haller, MD introduction 11:30 ReST Committee update on intraocular inflammation reported in patients who received Syfovre at the American Society of Retina Specialists annual meeting 13:44 The FDA approved Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Astellas Pharma 14:16 Novartis is discontinuing the development of GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration 14:36 How has the latest retina news affected patients and physicians? 14:53 The development of biosimilars 19:50 Discussion on pricing of products 21:57 The evolution and future of residency programs 23:34 Fun with retina drug names 27:15 Preview of episode 19 at OSN New York 29:46 Feedback, questions and guest suggestions at eyeluminaries@healio.com 30:15 Thanks for listening 30:27 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Julia Haller, MD, is Ophthalmologist-in-Chief and William Tasman, MD Endowed Chair at Wills Eye Hospital and Professor and Chair of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University in Philadelphia, PA. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Haller reports being on the board of directors at Bristol Myers Squibb, Opthea and Outlook Therapeutics. She is consultant to Aura Biosciences, Bionic Sight, Lowy Medical Research Institute and Regeneron.

Het leek een groot succes te worden: de beursgang van Instacart. Maar al op de tweede handelsdag worden beleggers abrupt uit die droom geholpen. De koers zakt onverwachts. Precies op de dag dat er nóg een bedrijf z'n debuut op Wall Street maakt. Zorgt Instacart voor koudwatervrees bij andere debutanten?  Verder gaat het over Ferrari. Dat is ongekend populair in de showroom, maar ook op de beurs. De interesse in het aandeel neemt alleen maar toe sinds het in het rijtje staat van Europa's grootste beursbedrijven, de Euro Stoxx 50. Toch is het twijfel over hoe lang dat beurssucces nog duurt.  Het aandeel Just Eat Takeaway gaat weer eens omhoog. Dat komt door een overwinning in Amerika. Want daar kan het mogelijk meer geld verdienen. Ben je benieuwd wat de beursdag van morgen je brengt? Dat komt goed, we hebben een vooruitblik voor je.  See omnystudio.com/listener for privacy information.

Stephen Barnett, our Director of Corporate Finance goes solo this week to cover three major topics in focus:Oddity IPO - The Israeli company ('where beauty meets Israeli technology') debuted on the Nasdaq. Lead book-running managers Morgan Stanley, Goldman Sachs, and Allen & Co. priced the IPO at $35, raising $424mn and achieving a first-day IPO 'pop' of over $35%!Cava IPO - The US fast food restaurant chain achieves a whopping 100% first-day pop on its opening day. Did underwriters J.P. Morgan, Citi, and Jefferies get the offer price wrong?CVC raises the largest buyout fund in history. The €26bn fund, which topped Blackstone's $26bn buyout fund, raised in 2019, suggests that investor demand for Private Equity is still high, despite clear headwinds.Free daily newsletter https://bit.ly/3Oeu4WkFree Finance Accelerator simulation https://bit.ly/3GoyV5rConnect with Stephen https://tinyurl.com/4h24y8jn Hosted on Acast. See acast.com/privacy for more information.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, are live at OCTANe OTS with Mark Leahey, Brent Saunders, Yari Mitchell and Robert Dempsey, discussing their experiences and influence across the ophthalmic space. ·       Welcome to the Eyeluminaries podcast :01 ·       Review of episode 16 with Stephen McLeod, MD :28 ·       Preview of episode 17, live at Octane OTS 1:00 ·       Introduce Mark Leahey, president & CEO for the Medical Device Manufacturers Association 1:23 ·       Challenges in medical device 2:19 ·       Is it possible for the government to reduce regulation of medical devices while still protecting patients? 4:32 ·       What is MDMA doing for sustainability? 6:50 ·       What is one issue that device manufacturers need to implement? 9:04 ·       Introduce Brent Saunders, Chairman and CEO of Bausch + Lomb 12:23 ·       What's different about Bausch + Lomb today that wasn't around when you first worked for the company? 13:27 ·       Tell us about other products at Bausch + Lomb. 19:22 ·       Introducing Yari Mitchell, the president of Y Factor Consulting, Inc. 23:31 ·       What have been the most important changes in the ophthalmic industry over the past couple of years? 24:58 ·       What advice would you give to an early-career person? 26:15 ·       Favorite memories of Jim Mazzo 29:14 ·       Introducing Robert Dempsey, CEO and President of AsclepiX Therapeutics 32:10 ·       What was it like to leap from medical sciences to a leadership position? 33:22 ·       Managing a pipeline that includes both retinal and cornea treatments 35:05 ·       How do you establish yourself as a competitor in age-related macular degeneration research in a mature and crowded market with limited resources? 36:10 ·       Creating a retinal treatment delivered via the suprachoroidal route 37:28 ·       The Holland Foundation For Sight Restoration seeking to spread access to eye care for patients and the importance of giving back 38:27 ·       Feedback, questions and guest suggestions at eyeluminaries@healio.com 44:00 ·       Thanks for listening 44:19 Robert Dempsey is the CEO and president of AsclepiX Therapeutics. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Mark Leahey is the president and CEO of the Medical Device Manufacturers Association. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Yari Mitchell is the president of Y Factor Consulting, Inc. Brent Saunders is the chairman and CEO of Bausch + Lomb. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Dempsey is the president and CEO of AsclepiX Therapeutics. Hovanesian consults widely in the ophthalmic field. Leahey is the president & CEO for the Medical Device Manufacturers Association. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Mitchell is the chief business development officer at AcuFocus and the president of Y Factor Consulting, Inc. Saunders is the chairman and CEO of Bausch + Lomb.

David Tayeh joined the Firm in 1999 as a Partner in the Private Equity team. From 2003 to 2005, David served as the Chief Financial Officer of Jostens, Inc., a former Investcorp portfolio company. Prior to Investcorp, David was a Vice President with DLJ. ​ In 2015, David rejoined Investcorp as the Head of North American Private Equity from CVC Capital Partners where he was a Partner from 2011. David is a member of Investcorp's Operating Committee, Investment Committee and the Financial & Risk Management Committee. ​ He currently serves on the board of directors of AlixPartners, CrossCountry Consulting, Fortune International, Health Plus Management, ICR, KSI Auto Parts, RESA Power, Revature, Roadsafe, Sunrise Produce, Alex Lee, and Arab-American Family Support Center. David holds a BA degree in Politics, Economics, Rhetoric and Law from the University of Chicago and an MBA from the Wharton School of Business at the University of Pennsylvania  

It's a little bit of everything this week -- first, some thoughts on the first week of Indian Wells, whose courts are slower than Daniil Medvedev's bathroom breaks (his words). We chat about Murray, Medvedev, Raducanu, Muchová, and the undeniable Ben Shelton. In business news, we talk about the WTA's official partnership with CVC Capital Partners, a private equity firm that has just promised a $150m in new and better revenue streams for women's tennis. Plus, Denis Shapovalov goes all in on gender pay equity, Netflix's Break Point announces a season two, and Rafa's all-time top 10 record is lost.      0:30 Some housekeeping and a thank you 3:10 Indian Wells week one: Daniil says it's not a hardcourt (and is he really wrong?) plus some chatter about the women's draw 10:00 Jonathan's new fave Ben Shelton 12:50 Private equity firm CVC invests $150m in WTA Ventures, a new commercial subsidiary 17:50 The Tsurenko-Steve Simon story - where is the reporting? 23:00 You got nothing to say now? Holger Rune gives himself the rare Double L  26:40 Denis Shapovalov honors his mom and says equal pay for equal work NOW! 38:25 Big up Sloane Stephens Foundation!  39:40 We're getting a Break Point season two whether we like it or not  45:10 Rafa's record for consecutive weeks in the top 10 will end at 912 46:25 Injury updates: Kontaveit plus where is Jen Brady?

Netflix stemmed its subscriber losses in the third quarter and Russia is using Iranian drones in its war against Ukraine. Plus, Europe's top private equity firm, CVC Capital Partners, is preparing to go public and the move has implications for the whole sector.Mentioned in this podcast:Netflix shares jump as it gains 2.4mn new subscribersCVC's biggest bet yet: the fiercely private buyout firm set to go publicMilitary briefing: Russia rolls out Iranian drones to ‘terrorise' UkraineThe FT News Briefing is produced by Fiona Symon, Sonja Hutson and Marc Filippino. The show's editor is Jess Smith. Additional help by Peter Barber, Michael Lello, David da Silva and Gavin Kallmann. Topher Forhecz is the FT's executive producer. The FT's global head of audio is Cheryl Brumley. The show's theme song is by Metaphor Music. Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.